Bayer, Algeta nab priority review for prostate cancer drug

Bayer's next big cancer prospect, radium-223 for castration-resistant prostate cancer, has won priority review status at the FDA. In-licensed from Norway's Algeta, Alpharadin is one of the pharma company's top late-stage prospects, following a string of regulatory wins on the development front. Analysts believe this treatment has good prospects at the regulatory agencies. Release | More

document.addEventListener("googletagEvent", function() { googletag.cmd.push(function() { googletag.display('ad-slot_1__mobile'); }); });  
Read more on